Generic Name and Formulations:
Iloprost 10mcg/mL, 20mcg/mL; soln for inhalation using I-neb or Prodose AAD System; preservative-free.
Indications for VENTAVIS:
Pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms to improve exercise ability and delay clinical worsening.
Initially 2.5mcg, if tolerated, uptitrate to 5micrograms 6–9 times daily based on tolerability (no more than every 2 hrs); max 45mcg/day. Monitor vital signs while initiating therapy. Hepatic impairment: consider increasing dosing interval (eg, 3–4 hours) between doses.
Do not start therapy if systolic BP <85 mmHg. Discontinue immediately if pulmonary edema occurs (may indicate pulmonary venous hypertension). Bleeding disorders. Avoid contact with eyes and skin, oral ingestion. COPD. Severe asthma. Acute pulmonary infections. Hepatic or renal impairment. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Potentiates hypotensive effect of vasodilators and antihypertensives. May potentiate anticoagulants. Do not mix with other drugs.
Vasodilation, increased cough, headache, lockjaw, insomnia, GI upset, hypotension, flu syndrome, back pain, abnormal lab tests (eg, increased GGT, alkaline phosphatase), tongue pain, palpitations, syncope, muscle cramps, hemoptysis, pneumonia, CHF, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, kidney failure.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC